CAR T cells have exhibited remarkable efficacy in combatting relapsed/refractory B-cell lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), as underscored by the approval of anti-CD19-CAR T cells [12, 13]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.